Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
71
datasets available to search
ShareScore release 0.9.0
Dataset results
71 results for “amyloid β”
Data from: Elovanoids counteract oligomeric β-Amyloid-induced gene expression and protect photoreceptors
Open the record for dataset details and reuse information.
Small molecule sequestration of amyloid-β as a drug discovery strategy for Alzheimer's disease
<p>These data describe the bound and unbound ensembles of a disordered peptide (amyloid beta) in the presence and absence of a small, drug-like molecule. The data were produced by metadynamic metainference simulations restrained with NMR chemical shift data. We used PLUMED version 2.6.0 and GROMACS 2018.3. All the data and PLUMED input files required to reproduce the metadynamic metainference results are available on PLUMED-NEST (www.plumed-nest.org), the public repository of the PLUMED consortium, as plumID:20.014.</p> <p>A Jupyter Notebook describing the analysis of these results is available from GitHub at https://github.com/vendruscolo-lab/amyloid-beta_small_mol/ in Metadynamic_metainference/Analysis.</p> <p>These data support the findings of the manuscript entitled "Small molecule sequestration of amyloid-β as a drug discovery strategy for Alzheimer's disease" by Heller <em>et al</em>. DOI: 10.1101/729392</p>
Association of amyloid-β CSF/PET discordance and tau load five years later
<p><strong>Objective</strong>: To investigate the association between discordant amyloid-β PET and CSF biomarkers at baseline and the emergence of tau pathology 5 years later.</p> <p><strong>Methods</strong>: We included 730 ADNI participants without dementia (282 cognitively normal, 448 mild cognitive impairment) with baseline [18F]Florbetapir PET and CSF Aβ42 available. Amyloid-β CSF/PET status was determined at baseline using established cut-offs. Longitudinal data was available for [18F]florbetapir (Aβ) PET (baseline to 4.3±1.9 years), CSF (p)tau (baseline to 2.0±0.1 years), cognition (baseline to 4.3±2.0 years), and [18F]flortaucipir (tau) PET (measured 5.2±1.2 years after baseline to 1.6±0.7 years later). We used linear mixed modelling to study the association between amyloid-β CSF/PET status and tau pathology measured in CSF or using PET. Additionally, we calculated the proportion of CSF+/PET- participants who during follow-up (i) progressed to amyloid-β CSF+/PET+, and/or (ii) became tau-positive based on [18F]flortaucipir PET.</p> <p><strong>Results</strong>: Amyloid-β CSF+/PET+ (N=318) participants had elevated CSF (p)tau levels and worse cognitive performance at baseline, while CSF+/PET- (N=80) participants were overall similar to the CSF-/PET- (N=306) group. Five years after baseline, [18F]flortaucipir PET uptake in the CSF+/PET- group (1.20±0.13) did not differ from CSF-/PET- (1.18±0.08, p=0.69), but was substantially lower than CSF+/PET+ (1.48±0.44, p<0.001). Of the CSF+/PET- subjects, 21/64 (33%) progressed to amyloid-β CSF+/PET+, whereas only one (3%, difference p<0.05) became tau-positive based on [18F]flortaucipir PET. </p> <p><strong>Conclusions</strong>: Amyloid-β load detectable by both CSF and PET seems to precede substantial tau deposition. Compared to participants with abnormal amyloid-β levels on both PET and CSF, the CSF+/PET- group has a distinctly better prognosis.</p>
Data from: A mix-and-click method to measure amyloid-β concentration with sub-micromolar sensitivity
Aggregation of amyloid-β (Aβ) protein plays a central role in Alzheimer's disease. Because protein aggregation is a concentration-dependent process, rigorous investigations require accurate concentration measurements. Owing to the high aggregation propensity of Aβ protein, working solutions of Aβ are typically in the low micromolar range. Therefore, an ideal Aβ quantification method requires high sensitivity without sacrificing speed and accuracy. Absorbance at 280 nm is frequently used to measure Aβ concentration, but the sensitivity is low with only one tyrosine and no tryptophan residues in the Aβ sequence. Here we present a fluorescence method for Aβ quantification using fluorescamine, which gives high fluorescence upon reaction with primary amines. We show that, using hen egg white lysozyme as a standard, fluorescence correlates linearly with primary amine concentration across a wide range of fluorescamine concentrations, from 62.5 to 1000 µM. The maximal sensitivity of detection is achieved at a fluorescamine concentration of 250 µM or higher. The fluorescamine method is compatible with the presence of dimethyl sulfoxide, which is commonly used in the preparation of Aβ oligomers, and limits the use of absorbance at 280 nm due to its high background reading. Using aggregation kinetics, we show that the fluorescamine method gives accurate concentration measurements at low micromolar range and leads to highly consistent aggregation data. We recommend the fluorescamine assay to be used for routine and on-the-fly concentration determination in Aβ oligomerization and fibrillization experiments.
Data from: A mix-and-click method to measure amyloid-β concentration with sub-micromolar sensitivity
Open the record for dataset details and reuse information.
Association of amyloid-β CSF/PET discordance and tau load five years later
Open the record for dataset details and reuse information.
Data from: High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Open the record for dataset details and reuse information.
A Chinese herbal formula, Gengnianchun, ameliorates β-amyloid peptide toxicity in a Caenorhabditis elegans model of Alzheimer’s disease
GEO Series GSE98195. Caenorhabditis elegans. 4 samples. Type: Expression profiling by high throughput sequencing.
BACE1 regulates expression of Clusterin in astrocytes for enhancing clearance of β-amyloid peptides
GEO Series GSE230116. Mus musculus. 8 samples. Type: Expression profiling by high throughput sequencing.
Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer’s disease [dataset2]
GEO Series GSE263038. Homo sapiens. 3 samples. Type: Expression profiling by high throughput sequencing.
Novel Alzheimer risk genes determine the microglia response to amyloid-β but not to TAU pathology
GEO Series GSE110741. Mus musculus. 96 samples. Type: Expression profiling by high throughput sequencing.
TREM2 Drives Microglia Response to Amyloid-β via SYK-dependent and -independent Paths [DAP12KI scRNA-seq]
GEO Series GSE210257. Mus musculus. 7 samples. Type: Expression profiling by high throughput sequencing.
Amyloid-β driven Alzheimer’s disease reshapes the colonic immune system in mice.
GEO Series GSE305697. mouse gut metagenome. 29 samples. Type: Other.
TREM2 Drives Microglia Response to Amyloid-β via SYK-dependent and -independent Paths [SYK and TREM2 scRNA-seq]
GEO Series GSE195518. Mus musculus. 17 samples. Type: Expression profiling by high throughput sequencing.
Typical western diet exacerbates dystrophic neurite pathology in APP/PS1 and APP/PS1/Tau mouse models by reducing the clustering of microglia around β-amyloid plaques
GEO Series GSE144746. Mus musculus. 45 samples. Type: Expression profiling by high throughput sequencing.
Endothelial Cell Senescence Stimulates Amyloid-β Phagocytosis and Barrier Function of Microglia Leading to Attenuation of Cognitive Impairment in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease
GEO Series GSE223394. Mus musculus. 4 samples. Type: Expression profiling by high throughput sequencing.
CASP4/Caspase-11 expression exacerbates neuroinflammation and amyloid-β deposition during Alzheimer’s disease [RRBS]
GEO Series GSE227194. Homo sapiens. 10 samples. Type: Methylation profiling by high throughput sequencing.
Brain-targeting liposome-based APOE2 gene delivery exacerbates soluble amyloid-β accumulation in AppNL-G-F mice
GEO Series GSE279476. Mus musculus. 23 samples. Type: Expression profiling by high throughput sequencing.
Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer’s disease [dataset3]
GEO Series GSE263079. Homo sapiens. 32 samples. Type: Other; Expression profiling by high throughput sequencing.
Circulating microRNAs associated to cerebrospinal fluid amyloid-β and phosphorylated tau levels as potential non-invasive biomarkers for mild cognitive impairment and Alzheimer’s disease
GEO Series GSE215789. Homo sapiens. 217 samples. Type: Non-coding RNA profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.